Article Versions Notes

Boongird S, Setthaudom C, Kitpermkiat R, Prasongtanakij S, Srisala S, Chuengsaman P, Nongnuch A, Assanatham M, Kiertiburanakul S, Malathum K, et al. Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). Vaccines. 2022; 10(7):1064. https://doi.org/10.3390/vaccines10071064

Boongird, Sarinya, Chavachol Setthaudom, Rungthiwa Kitpermkiat, Somsak Prasongtanakij, Supanart Srisala, Piyatida Chuengsaman, Arkom Nongnuch, Montira Assanatham, Sasisopin Kiertiburanakul, Kumthorn Malathum, and et al. 2022. "Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3)" Vaccines 10, no. 7: 1064. https://doi.org/10.3390/vaccines10071064

Boongird, S., Setthaudom, C., Kitpermkiat, R., Prasongtanakij, S., Srisala, S., Chuengsaman, P., Nongnuch, A., Assanatham, M., Kiertiburanakul, S., Malathum, K., Phuphuakrat, A., & Bruminhent, J. (2022). Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). Vaccines, 10(7), 1064. https://doi.org/10.3390/vaccines10071064